Yahoo
LSE - Delayed Quote GBp

Shield Therapeutics plc (STX.L)

6.10 +0.60 (+10.91%)
As of 2:49:00 PM GMT+1. Market Open.
Chart Range Bar
Loading chart for STX.L
  • Previous Close 5.50
  • Open 5.53
  • Bid 5.90 x --
  • Ask 6.10 x --
  • Day's Range 5.53 - 6.36
  • 52 Week Range 3.70 - 12.50
  • Volume 11,808,879
  • Avg. Volume 2,115,019
  • Market Cap (intraday) 65.265M
  • Beta (5Y Monthly) 1.72
  • PE Ratio (TTM) --
  • EPS (TTM) -0.01
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 16.67

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.

www.shieldtherapeutics.com

61

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 8/28/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

STX.L
38.07%
FTSE 100 (^FTSE)
8.99%

1-Year Return

STX.L
21.29%
FTSE 100 (^FTSE)
17.44%

3-Year Return

STX.L
37.44%
FTSE 100 (^FTSE)
47.50%

5-Year Return

STX.L
85.73%
FTSE 100 (^FTSE)
51.43%

Analyst Insights

View More

Analyst Price Targets

12.00
16.67 Average
6.10 Current
23.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    58.85M

  • Enterprise Value

    73.31M

  • Trailing P/E

    --

  • Forward P/E

    285.71

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.35

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    1.70

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -17.69%

  • Return on Assets (ttm)

    -4.37%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    58.62M

  • Net Income Avi to Common (ttm)

    -10.37M

  • Diluted EPS (ttm)

    -0.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.35M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.21M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: